FDG-PET and PET/CT - Part II

Indian Journal of Radiology and Imaging

Volumn 18, Issue 1, 2008, Pages 17-36

  Takalkar, Amol M ^a,b   El Haddad, Ghassan ^a   Lilien, David L ^a,b  

^a Biomedical Research Foundation of Northwest Louisiana   (United States)

^b Louisiana State University Health Sciences Center at Shreveport   (United States)

Author keywords

FDG; PET; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE;

ARTICLE; BREAST CANCER; CANCER STAGING; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; LUNG SMALL CELL CANCER; MELANOMA; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIATION DOSE; SCINTIGRAPHY; THYROID CANCER; UNITED STATES;

EID: 38349014108     PISSN: 09713026     EISSN: None     Source Type: Journal    
DOI: 10.4103/0971-3026.38504     Document Type: Article

References (86)

1. Takalkar AM, El-Haddad G, Lilien DL. FDG-PET and PET/CT - Part I. Indian J Radiol Imaging 2007;17:169-80.
2. Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986;314:884-8.
3. Warburg O, Wind F, Negelein E. The metabolism of tumors in body. J Gen Physiol 1927;8:519-30.
4. American Cancer Society. Cancer Facts and Figures 2007. Available from: http://www.cancer.org/docroot/stt/content/stt_1x_cancer_facts__figures_2007.asp.
5. Bailet JW, Abemayor E, Jabour BA, Hawkins RA, Ho C, Ward PH. Positron emission tomography: A new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope 1992;102:281-8.
6. Hannah A, Scott AM, Tochon-Danguy H, Chan JG, Akhurst T, Berlangieri S, et al. Evaluation of 18 F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer. Ann Surg 2002;236:208-17.
7. Di Martino E, Nowak B, Hassan HA, Hausmann R, Adam G, Buell U, et al. Diagnosis and staging of head and neck cancer: A comparison of modern imaging modalities (positron emission tomography, computed tomography, color-coded duplex sonography) with panendoscopic and histopathologic findings. Arch Otolaryngol Head Neck Surg 2000;126:1457-61.
8. Kau RJ, Alexiou C, Laubenbacher C, Werner M, Schwaiger M, Arnold W. Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with fluorodeoxyglucose F 18 in a routine clinical setting. Arch Otolaryngol Head Neck Surg 1999;125:1322-8.
9. Adams S, Baum RP, Stuckensen T, Bitter K, Hör G. Prospective comparison of 18F-FDG-PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998;25:1255-60.
10. Laubenbacher C, Saumweber D, Wagner-Manslau C, Kau RJ, Herz M, Avril N, et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med 1995;36:1747-57.
11. Schoder H, Carlson DL, Kraus DH, Stambuk HE, Gönen M, Erdi YE, et al. 18F-FDG-PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med 2006;47:755-62.
12. Schmid DT, Stoeckli SJ, Bandhauer F, Huguenin P, Schmid S, von Schulthess GK, et al. Impact of positron emission tomography on the initial staging and therapy in locoregional advanced squamous cell carcinoma of the head and neck. Laryngoscope 2003;113:888-91.
13. Johansen J, Eigtved A, Buchwald C, Theilgaard SA, Hansen HS. Implication of 18F-fluoro-2-deoxy-D-glucose positron emission tomography on management of carcinoma of unknown primary in the head and neck: A Danish cohort study. Laryngoscope 2002;112:2009-14.
14. Jungehulsing M, Scheidhauer K, Damm M, Pietrzyk U, Eckel H, Schicha H, et al. 2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head Neck Surg 2000;123:294-301.
15. Goodier MA, Takalkar A, Lilien DL, Lian TS, Kupferman TA, Nathan CO. Utility of Panendoscopy for unknown primary and negative PET. Otolaryngol Head Neck Surg 2006;135:S66.
16. Leon X, Quer M, Diez S, Orús C, López-Pousa A, Burgués J. Second neoplasm in patients with head and neck cancer. Head Neck 1999;21:204-10.
17. McCollum AD, Burrell SC, Haddad RI, Norris CM, Tishler RB, Case MA, et al. Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck 2004;26:890-6.
18. Minn H, Paul R, Ahonen A. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. J Nucl Med 1988;29:1521-5.
19. Ware RE, Matthews JP, Hicks RJ, Porceddu S, Hogg A, Rischin D, et al. Usefulness of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with a residual structural abnormality after definitive treatment for squamous cell carcinoma of the head and neck. Head Neck 2004;26:1008-17.
20. Kresnik E, Gallowitsch HJ, Mikosch P, Stettner H, Igerc I, Gomez I, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area. Surgery 2003;133:294-9.
21. Hickeson M, Zhuang H, Chacko TK, Alavi A. How high can the standardized uptake value be? Clin Nucl Med 2002;27:819.
22. Lowe VJ, Mullan BP, Hay ID, McIver B, Kasperbauer JL. 18F-FDG-PET of patients with Hurthle cell carcinoma. J Nucl Med 2003;44:1402-6.
23. Chud QD, Connor MS, Lilien DL, Johnson LW, Turnage RH, Li BD. Positron emission tomography (PET) positive thyroid incidentaloma: The risk of malignancy observed in a tertiary referral center. Am Surg 2006;72:272-5.
24. Schoder H, Yeung HW. Positron emission imaging of head and neck cancer, including thyroid carcinoma. Semin Nucl Med 2004;34:180-97.
25. Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif B, et al. 18F-FDG-PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 2007;48:221-6.
26. Chin BB, Patel P, Cohade C, Ewertz M, Wahl R, Ladenson P. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 2004;89:91-5.
27. van Tol KM, Jager PL, Piers DA, Pruim J, de Vries EG, Dullaart RP, et al. Better yield of fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid 2002;12:381-7.
28. Grunwald F, Biersack HJ. FDG-PET in thyroid cancer:thyroxine or not? J Nucl Med 2000;41:1996-8.
29. Haugen BR, Lin EC. Isotope imaging for metastaic thyroid cancer. Endocrinol Metab Clin North Am 2001;30:469-92.
30. Ong SC, Schoder H, Patel SG, Tabangay-Lim IM, Doddamane I, Gönen M, et al. Diagnostic accuracy of 18F-FDG-PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med 2007;48:501-7.
31. de Groot JW, Links TP, Jager PL, Kahraman T, Plukker JT. Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 2004;11:786-94.
32. Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: Results of a multicentre study. Eur J Nucl Med 2001;28:1671-6.
33. Goldsmith SJ, Kostakoglu L. Role of nuclear medicine in the evaluation of the solitary pulmonary nodule. Semin Ultrasound CT MR 2000;21:129-38.
34. Lowe VJ, Fletcher JW, Gobar L, Lawson M, Kirchner P, Valk P, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998;16:1075-84.
35. Lowe VJ, Hoffman JM, DeLong DM, Patz EF, Coleman RE. Semi-quantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 1994;35:1771-6.
36. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: A meta-analysis. JAMA 2001;285:914-24.
37. Matthies A, Hickeson M, Cuchiara A, Alavi A. Dual time point 18F-FDG-PET for the evaluation of pulmonary nodules. J Nucl Med 2002;43:871-5.
38. Zhuang H, Pourdehand M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, et al. Dual time point 18F-FDG-PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001;42:1412-7.
39. Gupta N, Gill H, Graeber G, Bishop H, Hurst J, Stephens T. Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions. Chest 1998;114:1105-11.
40. Tournoy KG, Maddens S, Gosselin R, Van Maele G, van Meerbeeck JP, Kelles A. Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: A prospective study. Thorax 2007;62:696-701.
41. Hellwig D, Ukena D, Paulsen F, Bamberg M, Kirsch CM; Onko-PET der Deutschen Gesellschaft fur Nuklearmedizin. Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors: Basis for discussion of the German Consensus Conference on PET in Oncology 2000. Pneumologie 2001;55:367-77.
42. Ahuja V, Coleman RE, Herndon J, Patz EF Jr. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998;83:918-24.
43. Ciernik IF, Dizendorf E, Baumert BG, Reiner B, Burger C, Davis JB, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): A feasibility study. Int J Radiat Oncol Biol Phys 2003;57:853-63.
44. Caggiano AJ, Vialotti C, Brunetti J. 4D PET/CT - early observations on integration and impact in radiation therapy planning for lung cancer. Int J Radiat Oncol Biol Phys 2004;60:S290.
45. Cerfolio RJ, Bryant AS, Winokur TS, Ohja B, Bartolucci AA. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 2004;78:1903-9.
46. Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in the evaluation of lymphoma. Cancer 2002;94:879-88.
47. Wirth A, Seymour JF, Hicks RJ, Ware R, Fisher R, Prince M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, galluim-67 scintigraphy and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 2002;112:262-8.
48. Shen YY, Kao A, Yen RF. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and galluim-67 citrate scintigraphy for detecting malignant lymphoma. Oncol Rep 2002;9:321-5.
49. Bar-Shalom R, Yefremov N, Haim N, Dann EJ, Epelbaum R, Keidar Z, et al. Camera-based FDG-PET and 67Ga SPECT in evaluation of lymphoma: Comparative study. Radiology 2003;227:353-60.
50. Zijlstra JM, Heokstra OS, Raijmakers PG, Comans EF, van der Hoeven JJ, Teule GJ, et al. 18 FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's Lymphoma. Br J Haematol 2003;123:454-62.
51. Spaepen K, Stroobants S, Verhoef G, Mortelmans L. Positron emission tomography with [(18)F]FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging 2003;30:S97-105.
52. Elstrom R, Guan L, Baker G, Nakhoda K, Vergilio JA, Zhuang H, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003;101:3875-6.
53. Friedberg J, Chengazi V. PET scans in the staging of lymphoma: Current status. Oncologist 2003;8:438-47.
54. Hoffman M, Kletter K, Diemling M, Becherer A, Pfeffel F, Petkov V, et al. positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 1999;10:1185-9.
55. Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med 2001;28:1707-23.
56. Hueltenschmidt B, Sautter-Bihl ML, Lang O, Maul FD, Fischer J, Mergenthaler HG, et al. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer 2001;91:302-10.
57. Schiepers C, Filmont JE, Czernin J. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003;30:S82-8.
58. Fuster DA, Chiang SA, Andreadis C, Guan L, Zhuang H, Schuster S, et al. Can [18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma? Nucl Med Commun 2006;27:11-5.
59. Schoder H, Meta J, Yap C, Ariannejad M, Rao J, Phelps ME, et al. Effect of whole-body F-FDG-PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 2001;42:1139-43.
60. Dizendorf EV, Baumert BG, von Schulthess GK, Lütolf UM, Steinert HC. Impact of whole-body 18F-FDG-PET on staging and managing patients for radiation therapy. J Nucl Med 2003;44:24-9.
61. Naumann R, Beuthien-Baumann B, Reiss A, Schulze J, Hänel A, Bredow J, et al. Substantial impact of FDG-PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 2004;90:620-5.
62. Burton C, Ell P, Linch D. The role of PET imaging in lymphoma. Br J Haematol 2004;126:772-84.
63. Rodriguez M, Rehn S, Ahlstrom H, Sundström C, Glimelius B. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 1995;36:1790-6.
64. Filmont J, Ko Yang F, Yap C. Prediction of malignancy grade using 18FDG-PET in Non Hodgkin's lymphoma patients: An urban legend? J Nucl Med 2002;43:79.
65. Schöder H, Noy A, Gönen M, Weng L, Green D, Erdi YE, et al. Intensity of 18Fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's Lymphoma. J Clin Oncol 2005;23:4643-51.
66. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
67. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86.
68. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107:52-9.
69. Spaepen K, Stroobants S, Verhoef G, Mortelmans L. Positron emission tomography with [F]FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging 2003;30:S97-105.
70. Toal DR. Tumor cell kinetics and cancer chemotherapy. Am J Nurs 1980;80:1802-4.
71. Lavely WC, Delbeke D, Greer JP, Morgan DS, Byrne DW, Price RR, et al. FDG-PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. Int J Radiat Oncol Biol Phys 2003;57:307-15.
72. Guay C, Lepine M, Verreault J, Bénard F. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med 2003;44:1225-31.
73. Reske SN. PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imaging 2003;30:S89-96.
74. Jerusalem G, Beguin Y, Fassotte MF, Belhocine T, Hustinx R, Rigo P, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003;14:123-30.
75. Freudenberg LS, Antoch G, Schutt P, Beyer T, Jentzen W, Müller SP, et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 2004;31:325-9.
76. Barrington SF, O'Doherty MJ. Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging 2003;30:S117-27.
77. Hoffman JM, Waskin HA, Schifter T, Hanson MW, Gray L, Rosenfeld S, et al. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 1993;34:567-75.
78. Pierce MA, Johnson MD, Maciunas RJ, Murray MJ, Allen GS, Harbison MA, et al. Evaluating contrast-enhancing brain lesions in patients with AIDS by using positron emission tomography. Ann Intern Med 1995;123:594-8.
79. Villringer K, Jager H, Dichgans M, Ziegler S, Poppinger J, Herz M, et al. Differential diagnosis of CNS lesions in AIDS patients by FDG-PET. J Comput Assist Tomogr 1995;19:532-6.
80. Wahl RL, Hutchins GD, Buchsbaum DJ, Liebert M, Grossman HB, Fisher S. 18F-2-deoxy-2 fluoro-D-glucose uptake into human xenografts. Cancer 1991;67:1544-50.
81. Fuster D, Chiang S, Johnson G, Schuchter LM, Zhuang H, Alavi A. Is 18F-FDG-PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma. J Nucl Med 2004;45:1323-7.
82. Rinne D, Baum RP, Hor G, Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole body 18F-fluorodeoxyglucose positron emission tomography: Results of a prospective study of 100 patients. Cancer 1998;82:1664-71.
83. Wagner JD, Schauwecker DS, Davidson D, Wenck S, Jung SH, Hutchins G. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol 2001;77:237-42.
84. Wong C, Silverman DS, Seltzer M, Schiepers C, Ariannejad M, Gambhir SS, et al. The impact of 2-deoxy-2[18F] fluoro-D-glucose whole body positron emission tomography for managing patients with melanoma: The referring physician's perspective. Mol Imaging Biol 2002;4:185-90.
85. Friedman KP, Wahl RL. Clinical use of positron emission tomography in the management of cutaneous melanoma. Semin Nucl Med 2004;34:242-53.
86. Loffler M, Weckesser M, Franzius CH, Nashan D, Schober O. Malignant melanoma and (18)F-FDG-PET: Should the whole body scan include the legs? Nuclearmedizin 2003;42:167-72